|
|
May 13, 2008
CHDI Foundation, Inc to carry out High Q Foundation’s research activities in Huntington’s Disease
May 1, 2008 – CHDI, Inc., recently renamed CHDI Foundation, Inc., and High Q Foundation, Inc. announced that CHDI has taken over primary responsibility for the types of Huntington’s disease research projects previously funded by High Q. CHDI will now be supporting the full gamut of Huntington’s disease research activities from basic discovery research through clinical development.
Read more...[pdf]
ISIS TO RECEIVE UP TO $9.9 MILLION IN FUNDING TO DEVELOP AN ANTISENSE DRUG FOR HUNTINGTON'S DISEASE
CARLSBAD, Calif., Oct. 26, 2007 –Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that CHDI, Inc. (CHDI), a non-profit foundation pursuing treatments for Huntington’s Disease (HD), will provide up to $9.9 million in funding to Isis for the discovery and development of an antisense drug for the treatment of HD, a fatal neurodegenerative disease.
Read more...[pdf]
Intellect Neurosciences, Inc. and CHDI, Inc. Enter into Compound Testing Agreement
New York, NY, September 20, 2007 /PRNewswire/ - Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on the development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, and CHDI, Inc., a non-profit organization pursuing the discovery and development of drugs to prevent or slow the progression of Huntington disease (HD), announced today that they have entered into an agreement under which CHDI will assess Intellect’s OXIGON™ as a potential therapy for Huntington disease.
Read more...[pdf]
ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
SAN DIEGO, Sept. 18 /PRNewswire/ -- ActiveSight, a division of Rigaku Americas Corporation, announced today that it will collaborate on a Fragment-based Lead Discovery (FBLD) Project with CHDI, Inc.
Read more...[pdf]
DANIEL P. VAN KAMMEN MD, PhD TO LEAD CHDI, INC.’S HUNTINGTON DISEASE CLINICAL DEVELOPMENT EFFORT
- MRSSI, Inc. announced today that Daniel P. van Kammen MD, PhD has joined as Chief Medical Officer. As such he will be responsible for the clinical development efforts of CHDI, Inc. CHDI was established in 2003 as a non-profit entity pursuing a biotech approach to finding therapies for Huntington disease (HD).
Read more...[pdf]
December 4, 2006
CHDI selects ENKAM's compounds for pre-clinical testing in Huntington disease transgenic model
- CHDI, Inc. (CHDI), a non-profit organization, together with ENKAM Pharmaceuticals A/S, the Copenhagen-based biotechnology company focused on cancer and neurodegenerative diseases, are pleased to announce that they have entered into a collaboration to test two of ENKAM's preclinical compounds in the area of Huntington disease (HD).
Read more...[pdf]
November 16, 2006
MethylGene and EnVivo Pharmaceuticals form collaboration with CHDI, Inc., in support of HDAC program
- November 16, 2006 – MethylGene Inc. (TSX: MYG) with its collaborator EnVivo Pharmaceuticals, today announced that they have entered into a collaborative agreement with CHDI, Inc., a non-profit organization that is pursuing biotechnology approaches to rapidly discover and develop treatments for Huntington disease (HD).
Read more...[pdf]
September 22, 2006
PsychoGenics expands Huntington disease research collaboration with High Q Foundation and CHDI
- PsychoGenics Inc. Tarrytown, New York has expanded its research collaboration with the High Q Foundation and CHDI, Inc. to phenotype transgenic mouse models of Huntington disease (HD) and evaluate potential therapeutics in those models.
Read more...[pdf]
September 21, 2006
Trophos SA and CHDI, Inc. extend partnership to develop promising compounds in models relevant to H
- Trophos SA, a biopharmaceutical company sepcializing in the discovery and development of drugs for neurodegenerative diseases and CHDI, Inc. (CHDI), a non-profit organization that supports translational research aimed at finding treatments that prevent or slow the progression of Huntington disease (HD), announced today the extension of a strategic collaboration to discover and develop drugs for Huntington disease.
Read more...[pdf]
September 18, 2006
CHDI selects Amphora Discovery's integrated discovery services in pursuit of Huntington disease cur
- Amphora Discovery announced today that CHDI, Inc., a non-profit organization pursuing a biotech approach to rapidly discover and develop drugs that prevent or slow Huntington disease (HD), has signed multiple agreements that provide access to Amphora Discovery's integrated contract discovery services.
Read more...[pdf]
August 10, 2006
CHDI selects Evotec as strategic drug discovery partner in the search for Huntington disease treatm
- Evotec AG today announced that CHDI, Inc., a not-for-profit organisation pursuing a biotech approach to finding therapies for Huntington disease, has chosen Evotec as a strategic partner for helping them advance its drug discovery programmes.
Read more...[pdf]
August 1, 2006
CHDI and Edison enter collaborative agreement to develop analogs of CoQ10
- CHDI and Edison Pharmaceuticals, Inc. today announced the formation of a partnership to develop analogs of CoQ10 selectively targeted to reach the brain and address the mitochondrial component of Huntington's disease.
Read more...[pdf]
August 15, 2005
CHDI, Inc. Announces Core Huntington’s Disease Drug Discovery Team
- Robert Pacifici, CSO-Drug Discovery & Development of MRSSI, announced today the hiring of several key members of the CHDI, Inc. team. CHDI, Inc. was established in 2003 as a non-profit entity pursuing a biotech approach to finding therapies for Huntington’s disease (HD).
Read more...[pdf]
June 30, 2005
CHDI, Inc.’s Huntington’s Disease Drug Discovery Effort Established in Los Angeles
- Robert Pacifici, CSO-Drug Discovery & Development of MRSSI, announced today that CHDI Inc.’s Huntington’s disease (HD) drug discovery and development effort will be managed from a new facility at 6080 Center Drive on the Howard Hughes Center campus in Los Angeles. The west coast location will be the base of operations for approximately twelve drug discovery professionals from the bio-pharmaceutical sector who will function as the strategic and tactical core to integrate a virtual (outsourced) effort.
Read more...[pdf]
|
|
